Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

RT-qPCR and RT-Digital PCR: A Comparison of Different Platforms for the Evaluation of Residual Disease in Chronic Myeloid Leukaemia

Mary Alikian, MSc, PhD, Alexandra S. Whale, Simon Cowen, Kim Piechocki, Michael John Griffiths, BSc, Alistair G Reid, BSc, PhD, Susanna Akiki, Jane F. Apperley, MD, Jim F. Huggett, Letizia Foroni

Blood (2016) 128 (22): 3104.

https://doi.org/10.1182/blood.V128.22.3104.3104

Published: 2016

Journal Articles

Excellent Outcome and Good Tolerability of Long-Term Imatinib in Patients with Chronic Myeloid Leukemia (CML)

Simone Claudiani, Nikhita Gupta, BSc, Ji Soo Baik, BSc, Simona Deplano, MDPhD, Renuka Palanicawander, Gareth Gerrard, Alistair G Reid, BSc, PhD, Richard M Szydlo, BSc, PhD, Dragana Milojkovic, Letizia Foroni, Jane F. Apperley, MD

Blood (2015) 126 (23): 2794.

https://doi.org/10.1182/blood.V126.23.2794.2794

Published: 2015

Journal Articles

Role of the MSC-Derived Exosomal and Endogenous JAK2-SET/PP2A-Beta Catenin-Modulator Mir-300 in Leukemic Stem/Progenitor Proliferation and Survival in CML

Blood (2015) 126 (23): 53.

https://doi.org/10.1182/blood.V126.23.53.53

Published: 2015

Journal Articles

BCR-ABL1 compound mutations in tyrosine kinase inhibitor–resistant CML: frequency and clonal relationships

Blood (2013) 121 (3): 489–498.

https://doi.org/10.1182/blood-2012-05-431379

Published: 2013

Includes: Supplemental data

Journal Articles

Can the Combination of the Measurement of BCR-ABL1 Transcript Levels At 3 and 6 Months Improve the Prognostic Value of the 3 Month Measurement?

Pratap Neelakantan, MRCP, Gareth Gerrard, PhD, Letizia Foroni, Dragana Milojkovic, Jane Apperley, Richard Szydlo, PhD, Marco Bua, Alistair G Reid, BSc, PhD, Katy Rezvani, MBBS, PhD, MRCP, FRCPath, John M Goldman, MD, David Marin

Blood (2012) 120 (21): 68.

https://doi.org/10.1182/blood.V120.21.68.68

Published: 2012

Journal Articles

EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors

Mustafa Daghistani, David Marin, Jamshid Sorouri Khorashad, Lihui Wang, Philippa C. May, Christos Paliompeis, Dragana Milojkovic, Valeria A. De Melo, Gareth Gerrard, John M. Goldman, Jane F. Apperley, Richard E. Clark, Letizia Foroni, Alistair G. Reid

Blood (2010) 116 (26): 6014–6017.

https://doi.org/10.1182/blood-2010-01-264234

Published: 2010

Includes: Supplemental data

Journal Articles

European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor

David Marin, Dragana Milojkovic, Eduardo Olavarria, Jamshid S. Khorashad, Hugues de Lavallade, Alistair G. Reid, Letizia Foroni, Katayoun Rezvani, Marco Bua, Francesco Dazzi, Jiri Pavlu, Matthias Klammer, Jaspal S. Kaeda, John M. Goldman, Jane F. Apperley

Blood (2008) 112 (12): 4437–4444.

https://doi.org/10.1182/blood-2008-06-162388

Published: 2008

Journal Articles

Regulation of Multiple Myeloma Survival and Progression by CD1d

Emmanouil Spanoudakis, Ming Hu, Kikkeri Naresh, Evangelos Terpos, Valeria Melo, Alistair G Reid, BSc, PhD, Ioannis Kotsianidis, Amin Rahemtulla, MBBS, PhD, FRCP, Anastasios Karadimitris

Blood (2008) 112 (11): 2720.

https://doi.org/10.1182/blood.V112.11.2720.2720

Published: 2008

Journal Articles

Common Submicroscopic Genomic Imbalances Accompany the Ph Chromosome at Diagnosis in Chronic Myeloid Leukemia

Jamshid S Khorashad, MD, Valeria A De Melo, Heike Fiegler, PhD, Gareth Gerrard, PhD, Dan Brudzevsky, PhD, David Marin, MD, Jane F. Apperley, MBChB, FRCP, FRCPath, John M Goldman, DM, FRCP, FRCPath, Letizia Foroni, MD, PhD, FRCPath, Alistair G Reid, PhD

Blood (2008) 112 (11): 3113.

https://doi.org/10.1182/blood.V112.11.3113.3113

Published: 2008

Journal Articles

Incorporating Marrow Plasma Cell Infiltration at Diagnosis and Cytogenetic Features into Prognostic Scoring at Point of Autologous Stem Cell Transplantation for Multiple Myeloma

Matthias Klammer, MD, MRCP, FRCPath, Chrissy Giles, B.A.(Hons), Alistair G Reid, BSc, PhD, Fiona M Ross, DPhil, Richard M. Szydlo, Jiri Pavlu, MRCP., FRCPath, Jane F. Apperley, MBChB, FRCP, FRCPath, Amin Rahemtulla, MBBS, PhD, FRCP

Blood (2008) 112 (11): 3319.

https://doi.org/10.1182/blood.V112.11.3319.3319

Published: 2008

Journal Articles

In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib

Jamshid S. Khorashad, Dragana Milojkovic, Puja Mehta, Mona Anand, Sara Ghorashian, Alistair G. Reid, Valeria De Melo, Anna Babb, Hugues de Lavallade, Eduardo Olavarria, David Marin, John M. Goldman, Jane F. Apperley, Jaspal S. Kaeda

Blood (2008) 111 (4): 2378–2381.

https://doi.org/10.1182/blood-2007-06-096396

Published: 2008

Journal Articles

Deletions Adjacent to BCR and ABL Breakpoints Occur in a Substantial Minority of Chronic Myeloid Leukaemia Patients with Masked Philadelphia Rearrangements.

Valeria A. De Melo, Paul Kotzampaltiris, Elisabeth Nacheva, MD, PhD, David Marin, MD, Jane F. Apperley, MD, PhD, Alistair G. Reid, PhD

Blood (2007) 110 (11): 2929.

https://doi.org/10.1182/blood.V110.11.2929.2929

Published: 2007

Journal Articles

Philadelphia-negative clonal hematopoiesis is a significant feature of dasatinib therapy for chronic myeloid leukemia

Valeria A. S. De Melo, Dragana Milojkovic, Jamshid S. Khorashad, David Marin, John M. Goldman, Jane F. Apperley, Alistair G. Reid

Blood (2007) 110 (8): 3086–3087.

https://doi.org/10.1182/blood-2007-05-092437

Published: 2007

Journal Articles

Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions

Brian J. P. Huntly, Francois Guilhot, Alistair G. Reid, George Vassiliou, Evelin Hennig, Christina Franke, Jennie Byrne, Andre Brizard, Dietger Niederwieser, Julie Freeman-Edward, Gavin Cuthbert, Nick Bown, Richard E. Clark, Elizabeth P Nacheva, Anthony R Green, Michael W. N. Deininger

Blood (2003) 102 (6): 2205–2212.

https://doi.org/10.1182/blood-2002-09-2763

Published: 2003

Journal Articles

Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL-BCR expression, elevated BCR-ABL levels, or karyotypic instability

Brian J. P. Huntly, Anthony J. Bench, Eric Delabesse, Alistair G. Reid, Juan Li, Mike A. Scott, Lynda Campbell, Jennie Byrne, Eleanor Pinto, Andre Brizard, Deitger Niedermeiser, Elizabeth P. Nacheva, Francois Guilhot, Michael Deininger, Anthony R. Green

Blood (2002) 99 (12): 4547–4553.

https://doi.org/10.1182/blood.V99.12.4547

Published: 2002

Journal Articles

Deletions of the derivative chromosome 9 do not account for the poor prognosis associated with Philadelphia-positive acute lymphoblastic leukemia

Alistair G. Reid, Brian J. P. Huntly, Eveline Hennig, Dietger Niederwieser, Lynda J. Campbell, Nick Bown, Nick Telford, Helen Walker, Colin D. Grace, Michael W. Deininger, Anthony R. Green, Elisabeth P. Nacheva

Blood (2002) 99 (6): 2274–2275.

https://doi.org/10.1182/blood.V99.6.2274

Published: 2002

Journal Articles

Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia

Brian J. P. Huntly, Alistair G. Reid, Anthony J. Bench, Lynda J. Campbell, Nick Telford, Patricia Shepherd, Jeff Szer, H. Miles Prince, Paul Turner, Colin Grace, Elizabeth P. Nacheva, Anthony R. Green

Blood (2001) 98 (6): 1732–1738.

https://doi.org/10.1182/blood.V98.6.1732

Published: 2001

NARROW

RT-qPCR and RT-Digital PCR: A Comparison of Different Platforms for the Evaluation of Residual Disease in Chronic Myeloid Leukaemia

Excellent Outcome and Good Tolerability of Long-Term Imatinib in Patients with Chronic Myeloid Leukemia (CML)

Role of the MSC-Derived Exosomal and Endogenous JAK2-SET/PP2A-Beta Catenin-Modulator Mir-300 in Leukemic Stem/Progenitor Proliferation and Survival in CML

BCR-ABL1 compound mutations in tyrosine kinase inhibitor–resistant CML: frequency and clonal relationships

Can the Combination of the Measurement of BCR-ABL1 Transcript Levels At 3 and 6 Months Improve the Prognostic Value of the 3 Month Measurement?

EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors

European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor

Regulation of Multiple Myeloma Survival and Progression by CD1d

Common Submicroscopic Genomic Imbalances Accompany the Ph Chromosome at Diagnosis in Chronic Myeloid Leukemia

Incorporating Marrow Plasma Cell Infiltration at Diagnosis and Cytogenetic Features into Prognostic Scoring at Point of Autologous Stem Cell Transplantation for Multiple Myeloma

In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib

Deletions Adjacent to BCR and ABL Breakpoints Occur in a Substantial Minority of Chronic Myeloid Leukaemia Patients with Masked Philadelphia Rearrangements.

Philadelphia-negative clonal hematopoiesis is a significant feature of dasatinib therapy for chronic myeloid leukemia

Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions

Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL-BCR expression, elevated BCR-ABL levels, or karyotypic instability

Deletions of the derivative chromosome 9 do not account for the poor prognosis associated with Philadelphia-positive acute lymphoblastic leukemia

Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only